Table 1.
Baseline clinical and electrophysiologic characteristics of the participants in each group.
| Variables | ALS | PMA | HC | Statistic difference |
|---|---|---|---|---|
| Number of patients | 143 | 36 | 53 | N/A |
| Age | 61.57 ± 10.74 | 59.92 ± 10.81 | 62.98 ± 8.17 | NS |
| Gender (female:male) | 1.1 (75:68) | 0.2 (6:30) | 1.4 (31:22) |
PMA-ALS: p < 0.001 PMA-HC: p < 0.001 |
| Onset region (B/C/LS) | 45/48/50 | 8/13/15 | N/A | NS |
| Disease duration | 19.20 ± 19.73 | 22.44 ± 25.63 | N/A | NS |
| ALSFRS-R score | 36.47 ± 6.25 | 36.88 ± 5.74 | N/A | NS |
| subALSFRS-R score (for items 7–9) | 7.46 ± 2.96 | 7.26 ± 3.43 | N/A | NS |
| Clinical UMN sign | 130 (91%) | 0 (0%) | N/A | N/A |
| Clinical LMN sign | 109 (76%) | 29 (81%) | N/A | N/A |
ALS amyotrophic lateral sclerosis, PMA progressive muscular atrophy, HC healthy control, N/A not applicable, NS not significant, B bulbar, C cervical, LS lumbosacral, ALSFRS-R revised amyotrophic lateral sclerosis functional rating scale, UMN upper motor neuron, LMN lower motor neuron.